Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose in tumor patients

Journal of Nuclear Medicine

Volumn 39, Issue 11, 1998, Pages 1928-1936

  Virgolini, Irene ^a   Szilvasi, Istvan ^b   Kurtaran, Amir ^b   Angelberger, Peter ^b   Raderer, Markus ^b   Havlik, Ernst ^b   Vorbeck, Friedrich ^b   Bischof, Claudia ^b   Leimer, Maria ^b   Dorner, Guido ^b   Kletter, Kurt ^b   Niederle, Bruno ^b   Scheithauer, Werner ^b   Smith Jones, Peter ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

1,4,7,10 tetraazacyclododecane N,N',N',N'' tetraacetic acid lanreotide; Indium 111 octreotide; Radiation absorbed dose; Somatostatin receptor; Tumor therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N,N TETRAACETIC ACID LANREOTIDE; ANGIOPEPTIN; GADOTERIC ACID; INDIUM 111; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CARCINOID; CLINICAL ARTICLE; DOSE CALCULATION; DRUG DISTRIBUTION; DRUG SAFETY; DRUG UPTAKE; FEMALE; HUMAN; INTESTINE CANCER; LYMPHOMA; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIODIAGNOSIS; TUMOR LOCALIZATION;

EID: 0031742949     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-1249.
2. Smith-Jones PM, Stolz B, Bruns C, et al. Gallium-67/gallium-68-DFO-octreotide: a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317-325.
3. Anderson CJ, Pajeaun TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64 octreotide conjugates. J Nucl Med 1995;36:2315-2325.
4. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016-1022.
5. 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med 1996;23:1388-1399.
6. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide (VIP) receptor imaging for the localisation of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-1121.
7. Virgolini I, Raderer M, Kurtaran A, et al. Iodine-123-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996;23:685-692.
8. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995;36:1732-1739.
9. Raderer M, Becherer A, Kurtaran A, et al. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med 1996;37:1480-1487.
10. 111In-DTPA-D-Phe1-octreotide. Ann N Y Acad Sci 1994;733: 496-506.
11. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(suppl):57-61.
12. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992;89:251-255.
13. Yamada Y, Reisine S, Law SF, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992;6:2136-2142.
14. Yamada Y, Kagimoto S, Kubota A, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtypes. Biochem Biophys Res Commun 1993;195:844-852.
15. Yasuda K, Res-Domiano S, Breder CA, et al. Cloning of a novel somatostalin receptor. SST3, coupled to adenylate cyclase. J Biol Chem 1992;267:20422-20428.
16. Demchyschyn LL, Srikant CB, Sunahara RK, et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 1993;43:894-901.
17. Corness JD, Demchyschyn LL, Seeman P. A human somatostatin receptor (SSTR3). located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS 1993;321:279-284.
18. Rohrer L, Raulf F, Bruns C, Buetter R, Hofstaedter F, Schüle R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993;90:4196-4200.
19. Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M. Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 1997;27:645-647.
20. Reubi J, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-3459.
21. Virgolini I, Pangerl T, Bischof C, et al. Somatostatin (SST) and vasoactive intestinal peptide (VIP) receptor (R) subtype gene expression [Abstract]. Eur J Nucl Med 1996;29:1102(A).
22. Peck-Radosavljevic M, Yang Q, Leimer M, et al. The somatostatin receptor subtype 3 (SSTR) acts as a VIP-acceptor [Abstract]. Gastroenterology 1998;114:1172.
23. Virgolini I, Yang Q, Li S, Angelberger P, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994;54:690-700.
24. Smith-Jones P, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel tumor diagnostic and therapeutic somatostatin analog [Abstract]. J Nucl Med 1998;39:223P.
25. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Reston, VA: Society of Nuclear Medicine; 1988.
26. Stabin MG. MIRDOSE. Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-546.
27. Johansson L, Mattson S, Nosslin B, Svegborn SR. Effective dose from radiopharmaceuticals. Eur J Nucl Med 1993;19:933-938.
28. Reubi JC. In vitro identification of vasoactive peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995;36:1846-1853.
29. Krenning EP, Bakker WH, Kwekkeboom DJ, et al. Biodistribution of a new chelated somatostatin analogue, indium-111-DOTA-D-Phe-1-Tyr-3-octreotide. Comparison with indium-111-DTPA-D-Phe-1-octreotide in humans [Abstract]. J Nucl Med 1997; 38:103P.
30. Krenning Ep, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1 and iodine-123-Tyr-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur I Nucl Med 1993;20:716-731.
31. 111In-DTPA-D-Phe-1-octreotide in man assessed by whole body scintigraphy. Acta Radiology 1994;35:53-57.